GLIS2 and CCND1 expression levels in breast cancer patients

Article type: Research Article

Authors: Sadeghi, Minoosh^a | Gholizadeh, Majid^b | Safataj, Neda^{c; d} | Tahmasebivand, Mahsa^e | Mohajeri, Gholamreza^f | Lotfi, Hajie^g | Bostanabad, Saber Yari^h | Safar, Behnaz^a; | Salehi, Mansoor^{i; j;}

Affiliations: [a] Department of Genetics, Faculty of Science, Shahrekord University, Shahrekord, Iran | [b] Department of Hematology and Blood Banking, Faculty of Allied Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran | [c] Department of Genetics, Islamic Azad University, Shahrekord Branch, Shahrekord, Iran | [d] Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran | [e] Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran | [f] Department of Surgery, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran | [g] Cellular and Molecular Research Center, Research Institute for Prevention of Non-Communicable Disease, Qazvin University of Medical Sciences, Qazvin, Iran | [h] Department of Pharmacology, Faculty of Pharmacy, Istanbul Health and Technology University, Istanbul, Turkey | [i] Cellular, Molecular and Genetics Research Center, Isfahan University of Medical Sciences, Isfahan, Iran | [j] Medical Genetics Research Center of Genome, Isfahan University of Medical Sciences, Isfahan, Iran

Correspondence: [*] Corresponding authors: Dr. Behnaz Safar, Department of Genetics, Faculty of Science, Shahrekord University, Shahrekord, Iran. Tel.: +98 3832324419; E-mail: saffar_b@sci.sku.ac.ir and Dr. Mansoor Salehi, Cellular, Molecular, and Genetics Research Center, Isfahan University of Medical Sciences, Isfahan 8175954319, Iran and Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan 8175954319, Iran. Tel.: +98 3136246922; Fax: +98 3136258320; E-mail: m_salehi@med.mui.ac.ir, genome.res.cent@gmail.com

Abstract: BACKGROUND:Breast cancer (BC) is the most prevalent cancer in women, with increasing incidence and death rates in recent years. Disruptions of different signaling pathways partially cause breast cancer. Hence, different genes through particular pathways are involved in BC tumorigenesis. METHODS:In this study, we evaluated the expression level of GLIS2 and CCND1 genes in 50 patients. Also, in-silico analyses were used to enrich related signaling pathways involving the mentioned genes. RESULTS:The results showed an increased expression level of Cyclin D1 and decreased expression level of GLIS2 in BC patients. Moreover, a relationship between aberrant expression levels of GLIS2 and CCND1 and BC development was determined. CONCLUSION:These observations could help uncover new therapeutic targets for treating patients with BC in the progressive stage.

Keywords: Breast cancer, GLIS2 , CCND1 , signaling pathway

DOI: 10.3233/BD-220068

Journal: Breast Disease, vol. 42, no. 1, pp. 251-259, 2023